IMCC IM Cannabis Corp.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
4.72
P/S
0.45
EV/EBITDA
-80.47
DCF Value
$-12.16
FCF Yield
-1.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
24.8%
Operating Margin
-51.6%
Net Margin
-3.0%
ROE
-24.4%
ROA
-2.8%
ROIC
-95.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $6.3M | $-1.7M | $— |
| Q4 null | $11.2M | $-5.5M | $— |
| FY null | $54.7M | $-11.3M | $— |
| Q3 null | $13.9M | $-3.7M | $— |
Analyst Ratings
View AllConsensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
IL
Exchange
—
Beta
2.02
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel, Germany, and Canada. It offers cannabis flowers and strain specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, and pressed hash offerings under the WAGNERS and Highland Grow brands. The company serves medical patients and adult-use recreational consumers. IM Cannabis Corp. is headquartered in Tel Aviv-Yafo, Israel.